Free tool
FAERS Monitor: Zanaflex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021447 or its brand name (Zanaflex, Tizanidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
18,291
Serious
10,734
59% of reports
Hospitalization
5,347
Death reported
898
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue1,549
- nausea1,482
- pain1,479
- headache1,431
- drug ineffective1,265
- fall1,047
- dizziness950
- dyspnoea899
- diarrhoea896
- arthralgia824
- vomiting788
- depression777
- asthenia768
- back pain741
- anxiety699
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 314 |
| 2005 | 356 |
| 2006 | 337 |
| 2007 | 237 |
| 2008 | 314 |
| 2009 | 364 |
| 2010 | 494 |
| 2011 | 521 |
| 2012 | 700 |
| 2013 | 584 |
| 2014 | 727 |
| 2015 | 1,094 |
| 2016 | 1,403 |
| 2017 | 1,034 |
| 2018 | 1,054 |
| 2019 | 1,013 |
| 2020 | 992 |
| 2021 | 867 |
| 2022 | 1,234 |
| 2023 | 1,187 |
| 2024 | 1,249 |
| 2025 | 1,269 |
| 2026 | 946 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,868 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| depressionSignal | 777 | 3.9 | 3.7 | 1,712 |
| back painSignal | 741 | 3.7 | 3.4 | 1,452 |
| fallSignal | 1,047 | 3.6 | 3.4 | 2,014 |
| anxietySignal | 699 | 2.8 | 2.6 | 834 |
| painSignal | 1,479 | 2.8 | 2.6 | 1,721 |
| headacheSignal | 1,431 | 2.6 | 2.5 | 1,483 |
| astheniaSignal | 768 | 2.4 | 2.2 | 605 |
| fatigueSignal | 1,549 | 2.3 | 2.2 | 1,166 |
| arthralgiaSignal | 824 | 2.3 | 2.1 | 603 |
| dizzinessSignal | 950 | 2.2 | 2.1 | 629 |
| nauseaSignal | 1,482 | 2.2 | 2.1 | 951 |
| vomiting | 788 | 1.9 | 1.8 | 359 |
| dyspnoea | 899 | 1.8 | 1.7 | 345 |
| diarrhoea | 896 | 1.6 | 1.5 | 205 |
| drug ineffective | 1,265 | 1.1 | 1.0 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.